The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]
NYS Entity Status
NYS Filing Date
JULY 18, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - LEGAL DRUGS INC
Around the Web
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
- Food & Wine Magazine Will Leave New York for Alabama
By STEPHANIE STROM - Friday Jun 23, 2017
The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.
- Most hated man in US soccer accused of ties to drug kingpin
By Brian Lewis, Kaja Whitehouse - Wednesday Aug 9, 2017
Rafael “Rafa” Marquez – who played for the NY Red Bulls before becoming captain of Mexico’s National Team – has been secretly acting as a frontman for a Mexican drug kingpin, according to the US Treasury Dept. Marquez, 37, is one of close to two dozen people the Treasury Dept. on Wednesday said has been helping hide...
- 'El Chapo' seeking new lawyers in US drug trafficking case
By TOM HAYS, Associated Press - Monday Aug 14, 2017
NEW YORK (AP) — Mexican drug lord and escape artist Joaquin "El Chapo" Guzman wants to hire new lawyers in his U.S. drug trafficking case, but there's questions about how they'll get paid.In phone interviews with The Associated Press last week, the lawyer, Jeffrey Lichtman, said he's more concerned about getting the court to sign off on the change of lawyers than about legal fees.Mexico extradicted Guzman in January to the U.S., where he pleaded not guilty to charges that his drug trafficking operation, the Sinaloa cartel, laundered billions of dollars and oversaw a ruthless campaign of murders and kidnappings.
- Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
By Ben Fidler - Monday Sep 11, 2017
A new drug for patients who have a hard time controlling their asthma could be nearing an FDA review. Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) and partner Sanofi this morning are touting results this morning from a 1,902-patient Phase 3 study called Liberty Asthma Quest. In it, their injectable antibody drug dupilumab (Dupixent), already approved […]
- NY AG presses TransUnion, Experian for cybersecurity details
By DAVID KLEPPER, Associated Press - Tuesday Sep 19, 2017
ALBANY, N.Y. (AP) — New York Attorney General Eric Schneiderman is pressing TransUnion and Experian to explain what cybersecurity they have in place to protect sensitive consumer information following a recent breach at Equifax that exposed the data of 143 million Americans.In letters to executives at the two credit monitoring companies, the Democratic attorney general asked them to describe their existing security systems as well as what changes they've made since the Equifax cyberattack."The unprecedented data breach experienced by Equifax Inc.